BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation growth accelerates

Q3 FY2026 stock-based compensation of $172.56B rose 350178.8% year over year, ahead of the +92559.3% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 227876.9% from the prior quarter. Over 3 fiscal years it compounded at -2.6% a year.

Context

  • Stock-based compensation amounted to 5.6% of revenue in FY2025, down 1.4 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +350178.8% holds above the trailing-twelve-month pace of +92559.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$172.56B+227876.9% QoQ
Last fiscal yearDec 2025
$181.41M-10.0% YoY
LTMSep 2026
$172.73B+92559.3% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+350178.8%——
1 year-10.0%——
3-year CAGR-2.6%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
181.41M USD
Year-over-year change
-10.0%
4-year CAGR
-2.1%

Stock-Based Compensation vs competitors

How BMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +92559.3% is the highest of 11, against a peer median of -3.3%.
  • Stock-based compensation amounts to 16.8% of revenue for BMRN, versus a peer median of 9.4%.
BMRN Competitors
Stock-Based Compensation for BMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$172.73B USD+92559.3%-2.6%16.8%
VRTXVertex Pharmaceuticals IncorporatedLTM Jun 2026$689.1M USD+0.5%+11.8%5.5%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$336.62M USD+10.1%+14.7%7.0%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$142.83M USD-11.3%+5.5%21.3%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$132.29M USD+4.4%+10.1%13.8%
INSMInsmed IncorporatedLTM Jun 2026$118.44M USD-11.8%+38.3%10.4%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$111.95M USD-7.0%+13.3%15.7%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$84.66M USD+15.0%-12.3%8.4%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$72.84M USD+70.9%+5.6%11.2%
PHARPharming Group N.V.LTM Mar 2026$3.48M USD-33.4%—0.9%
ASNDAscendis Pharma A/SLTM Sep 2026€0 EUR-100.0%—0.0%
Peer median (excluding BMRN) —-3.3%+10.9%9.4%

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(64.08M)141.56M167.65M426.86M348.9M
Depreciation & Amortization108.04M101.97M104.39M96.43M79.56M
Deferred Income Tax(15.61M)(52.09M)(44.98M)56.1M48.74M
Stock-Based Compensation197.26M196.31M207.1M201.57M181.41M
Change in Working Capital66.03M(96.38M)(336.54M)(216.4M)(108.68M)
Accounts Receivables65.57M(82.03M)(190.44M)(57.91M)(228.05M)
Inventory(35.06M)(68.26M)(157.06M)(63.53M)119.21M
Accounts Payables15.69M59.02M68.85M(32.24M)66.14M
Other Working Capital19.83M(5.1M)(57.9M)(62.72M)(65.97M)
Other Non-Cash Items12.89M(115.47M)61.65M8.29M278.07M
Operating Cash Flow304.54M175.9M159.26M572.84M827.99M
Capital Expenditures(119.23M)(120.96M)(107.61M)(97.42M)(103.04M)
Acquisitions (Net)0000(285.19M)
Purchases of Investments(937.14M)(611.81M)(868.5M)(410.25M)(355.88M)
Sales of Investments691.05M620M864.86M633.02M337.8M
Other Investing Activities(24.64M)103.33M(10.92M)(853K)(7.94M)
Investing Cash Flow(366.31M)(20.03M)(111.24M)136.49M(414.24M)
Debt Repayment(3.04M)(2.61M)(2.29M)(494.99M)0
Common Stock Issued069.33M69.35M014.46M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.99M(85.38M)(85.79M)(31.46M)(56.85M)
Financing Cash Flow(48K)(18.65M)(18.73M)(526.45M)(42.39M)
Effect of Forex Changes(57K)32K1.31M4.83M(2.52M)
Net Change in Cash(61.88M)137.26M30.6M187.72M368.84M
Free Cash Flow185.31M54.94M51.65M475.42M724.96M

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.